1. Home
  2. Vol 5, No 2 (2021)
  3. Choirunnisa

Hubungan Hipertensi dengan Mortalitas Pasien Covid-19 di Tangerang Selatan

Choirunnisa Choirunnisa, Helda Helda

Abstract


Covid-19 (Coronavirus Disease-2019) adalah penyakit yang disebabkan oleh virus SARS-CoV-2 (Severe Acute Respiratory Syndrome-Coronavirus-2). Usia tua (≥65 tahun), jenis kelamin laki-laki, hipertensi, penyakit kardiovaskular, diabetes, PPOK dan kanker dapat meningkatkan risiko kematian akibat Covid-19. Kota Tangerang Selatan berpotensi mengalami kenaikan kasus Covid-19 karena berbatasan langsung dengan DKI Jakarta yang merupakan episentrum persebaran Covid-19, sehingga peneliti tertarik untuk melakukan penelitian ini. Desain penelitian ini adalah studi analitik kasus kontrol menggunakan data sekunder dari penelusuran epidemiologi (PE) Dinas Kesehatan Kota Tangerang Selatan bulan Maret 2020-Juli 2021. Data PE diperoleh dari portal New All Record (NAR) yang memuat data pasien Covid-19 termasuk identitas, gejala, komorbid, dan status pasien yang dikumpulkan dari wawancara atau anamnesis di fasyankes. Variabel independen pada penelitian ini adalah hipertensi dan variabel dependen adalah kematian pasien Covid-19 terkonfirmasi positif. Variabel kovariat yang diteliti antara lain usia, jenis kelamin, diabetes mellitus (DM), penyakit kardiovaskular (CVD), gangguan imunologi, penyakit ginjal kronik (PGK), penyakit paru obstruktif kronik (PPOK), dan obesitas. Jumlah sampel kelompok kasus dan kontrol masing-masing sebanyak 344 sehingga total sampel adalah 688 sampel. Analisis data yang dilakukan adalah univariat, bivariat, dan multivariat. Proporsi pasien Covid-19 yang memiliki hipertensi pada kelompok kasus adalah 44.77% dan pada kelompok kontrol sebanyak 8.14%. Analisis multivariat dengan regresi logistik dihasilkan OR=9.08 (p-value=0.000; 95% CI 4.62-17.84) setelah dikontrol dengan usia, DM, PGK, interaksi hipertensi dan usia, hipertensi dan DM, dan hipertensi dan penyakit kardiovaskular. Penelitian ini memiliki bias informasi karena pengumpulan data berdasarkan anamnesis.

Keywords


Hipertensi, covid-19, diabetes mellitus, mortalitas, penyakit kardiovaskular

Full Text:

PDF

References


Coronavirus. Accessed October 14, 2021. https://www.who.int/health-topics/coronavirus#tab=tab_1

World Health Organization. 15-Novel Coronavirus (2019-nCoV). World Heal Organ. 2020;(February):1-7. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1_2

WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. Accessed October 14, 2021. https://covid19.who.int/

Peta Sebaran | Covid19.go.id. Accessed October 14, 2021. https://covid19.go.id/peta-sebaran

TANGSEL TANGGAP COVID-19. Accessed October 14, 2021. https://lawancovid19.tangerangselatankota.go.id/

Han Y, Yang H. The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-19): A Chinese perspective. J Med Virol. 2020;92(6):639-644. doi:10.1002/jmv.25749

Susilo A, Rumende CM, Pitoyo CW, et al. Coronavirus Disease 2019: Tinjauan Literatur Terkini. J Penyakit Dalam Indones. 2020;7(1):45. doi:10.7454/jpdi.v7i1.415

Parohan M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Aging Male. 2020;23(5):1397-1405. doi:10.1080/13685538.2020.1774748

RI KK. PEDOMAN PENCEGAHAN DAN PENGENDALIAN CORONAVIRUS DISESASE (COVID-19). Published online 2020. doi:10.14710/jkli.19.2.i-iii

Jakhmola S, Indari O, Baral B, Kashyap D. Comorbidity Assessment Is Essential During COVID-19 Treatment. 2020;11(August):1-7. doi:10.3389/fphys.2020.00984

Albitar O, Ballouze R, Ooi JP, Sheikh Ghadzi SM. Risk factors for mortality among COVID-19 patients. Diabetes Res Clin Pract. 2020;166:108293. doi:10.1016/j.diabres.2020.108293

Yin T, Li Y, Ying Y, Luo Z. Prevalence of comorbidity in Chinese patients with COVID-19: systematic review and meta-analysis of risk factors. BMC Infect Dis. 2021;21(1):1-13. doi:10.1186/s12879-021-05915-0

Pititto BDA, Dualib PM, Zajdenverg L, Dantas JR. Severity and mortality of COVID 19 in patients with diabetes , hypertension and cardiovascular disease : a meta ‑ analysis. Diabetol Metab Syndr. 2020;4:1-12. doi:10.1186/s13098-020-00586-4

Kemenkes RI. Hasil Riset Kesehatan Dasar Tahun 2018. Kementrian Kesehat RI. 2018;53(9):1689-1699.

Nandy K, Salunke A, Pathak SK, et al. Coronavirus disease (COVID-19): A systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events. Diabetes Metab Syndr Clin Res Rev. 2020;14(5):1017-1025. doi:10.1016/j.dsx.2020.06.064

Guan W, Liang W, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China : a. 2020;(March 2020). doi:10.1183/13993003.00547-2020

Peña JE de la, Rascón-Pacheco RA, Ascencio-Montiel I de J, et al. Hypertension, Diabetes and Obesity, Major Risk Factors for Death in Patients with COVID-19 in Mexico. Arch Med Res. 2021;52(4):443-449. doi:10.1016/j.arcmed.2020.12.002

Gao C, Cai Y, Zhang K, et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J. 2020;41(22):2058-2066. doi:10.1093/eurheartj/ehaa433

Imam Z, Odish F, Gill I, et al. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. J Intern Med. 2020;288(4):469-476. doi:10.1111/joim.13119

Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3

Drew C, Adisasmita AC. Gejala dan komorbid yang memengaruhi mortalitas pasien positif COVID-19 di Jakarta Timur , Maret-September 2020. 2021;3(3):274-283.

Pradhan A, Olsson PE. Sex differences in severity and mortality from COVID-19: are males more vulnerable? Biol Sex Differ. 2020;11(1):1-11. doi:10.1186/s13293-020-00330-7

Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363-374. doi:10.1038/s41577-020-0311-8

Huang J, Xiao Y, Zheng P, et al. Distinct neutrophil counts and functions in newly diagnosed type 1 diabetes, latent autoimmune diabetes in adults, and type 2 diabetes. Diabetes Metab Res Rev. 2019;35(1):1-10. doi:10.1002/dmrr.3064

Li J, Guo T, Dong D, et al. Defining heart disease risk for death in COVID-19 infection. Qjm. 2020;113(12):876-882. doi:10.1093/qjmed/hcaa246

Najafi S, Rajaei E, Moallemian R, Nokhostin F. The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach. Clin Rheumatol. 2020;39(11):3223-3235. doi:10.1007/s10067-020-05376-x

Zarębska-Michaluk D, Jaroszewicz J, Rogalska M, et al. Impact of Kidney Failure on the Severity of COVID-19. J Clin Med. 2021;10(9):2042. doi:10.3390/jcm10092042

Gerayeli F V., Milne S, Cheung C, et al. COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine. 2021;33:100789. doi:10.1016/j.eclinm.2021.100789

Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. BMJ. 2020;369(March):1-12. doi:10.1136/bmj.m1985

Azar WS, Njeim R, Fares AH, et al. COVID-19 and diabetes mellitus: how one pandemic worsens the other. Rev Endocr Metab Disord. 2020;21(4):451-463. doi:10.1007/s11154-020-09573-6




DOI: http://dx.doi.org/10.7454/epidkes.v5i2.5265

Refbacks

  • There are currently no refbacks.